Regenerative Medical Technology Group Inc.

Regenerative Medical Technology Group Inc. is a U.S.-based regenerative medicine company centered on stem cell-related products, clinical services, practitioner education, and manufacturing support. Its business combines direct patient treatments, product commercialization, training programs, and clinic-network operations across international markets.

−11,5 %

55,1 %

−153,2 %

+24,2 %

0.03

0.03

— Regenerative Medical Technology Group Inc.
%
Regenerative medicine products40% Cell therapy kits, exosome therapies, peptides, biologics, and related consumables sold to clinics and practitioners.
Clinical treatment services30% Direct patient care and treatment procedures delivered through company-operated or affiliated clinics.
Education and certification15% Training, seminars, congresses, and practitioner certification through the ISSCA platform.
Distribution and support services10% Logistics, inventory management, technical support, and sales training for external partners and clinics.
Manufacturing and development5% Manufacturing scale-up and product development for new regenerative medicine formulations.

The company sells to medical practitioners, clinics, and external distribution partners that use or resell regenerative...

  • Medical practitioners and clinicsprimary

    Buy stem cell kits, products, equipment, and training to deliver regenerative medicine protocols.

  • Direct patient care customersprimary

    Patients receiving treatments at company clinics, generating service revenue and product pull-through.

  • External distribution partnerssecondary

    Qualified partners that market and distribute the company's products in their territories.

  • Education and certification participantssecondary

    Practitioners and institutions that attend ISSCA programs, seminars, and certification courses.

  • Medical institutions and research collaboratorsemerging

    Universities and clinical organizations engaged for protocol development and validation.

The company operates internationally, with clinical and distribution activity spanning the Americas, the Middle East,...

  • •Clinic operations in Cancun, Mexico
  • •Clinic presence in Dubai, United Arab Emirates
  • •Planned expansion into Puerto Rico and Argentina
  • •Potential entry into Saudi Arabia
  • •U.S. market development tied to regulatory progress

The company is building a vertically integrated regenerative medicine platform that combines product development,...

01
Clinic network expansionshort-term

Direct patient care adds recurring revenue and creates demand for the company's products.

02
Manufacturing scale-upshort-term

Greater production capacity supports product availability, quality control, and vertical integration.

03
Product diversificationmedium-term

New formulations broaden the addressable market and reduce reliance on a narrow product set.

04
Education platform expansionmedium-term

Training and certification support practitioner adoption and reinforce the company's protocol ecosystem.

05
U.S. market entrymedium-term

The U.S. offers a large market but requires careful regulatory navigation and clinical credibility.

The business depends on regulatory acceptance of regenerative medicine, clinical adoption, and the ability to fund...

critical

Funding and going-concern risk

The company states it will require additional funding to finance growth and strategic objectives.

Scope
Corporate-wide
Materiality
high
high

Regulatory risk in regenerative medicine

Clinical use of stem cell and related therapies depends on evolving rules and approvals in each market.

Scope
U.S., Mexico, UAE, and other expansion markets
Materiality
high
high

Execution risk in clinic expansion

New clinics require local infrastructure, staffing, compliance, and patient demand to succeed.

Scope
Puerto Rico, Argentina, Saudi Arabia, U.S.
Materiality
high
high

Manufacturing and quality control risk

Scaling production across locations can affect product consistency and regulatory compliance.

Scope
Manufacturing footprint
Materiality
high
high

Reputation and clinical outcome risk

Patient-facing regenerative therapies are sensitive to safety, efficacy, and practitioner trust.

Scope
Clinic network and education platform
Materiality
high
ASC 606 revenue recognition
Product shipments and treatment sessions may be recognized in different periods
Goodwill and acquisition accounting
Could create non-cash charges if acquired value declines
Derivative liability valuation
May introduce volatility in reported results
Going-concern assessment
Affects balance sheet presentation and investor risk assessment
Fair value estimates
Can materially affect reported equity and expenses

Harvard Apparatus Regenerative Technology, Inc.

HRGN · Surgical & Medical Instruments & Apparatus

Organogenesis Holdings Inc.

ORGO · Pharmaceutical Preparations

BioRestorative Therapies, Inc.

BRTX · Services-Misc Health & Allied Services, NEC

International Stem Cell CORP

ISCO · Pharmaceutical Preparations

RetinalGenix Technologies Inc.

RTGN · Surgical & Medical Instruments & Apparatus

Metagenomi Therapeutics, Inc.

MGX · Biological Products, (No Diagnostic Substances)

: 29/04/2026